AXGN
$32.75
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide.
Intraday
Recent News
Do Options Traders Know Something About Axogen Stock We Don't?
Investors need to pay close attention to AXGN stock based on the movements in the options market lately.
AxoGen Says BLA Approval Secures Avance Use, Boosts Coverage Talks and Reimbursement Momentum
AxoGen (NASDAQ:AXGN) executives said a newly secured Biologics License Application (BLA) approval has preserved the company’s ability to serve patients across a broad range of peripheral nerve repair needs, while also helping address remaining reimbursement and coverage barriers that have affected a
AxoGen Conference: AVANCE BLA Approval, Debt Paydown Fuel 2026 Growth Target of 18%+
AxoGen (NASDAQ:AXGN) executives outlined a year of accelerating commercial momentum, recent balance sheet improvements, and the operational implications of its December Biologics License Application (BLA) approval for AVANCE during a recent investor discussion. Business momentum and commercial perf
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference
AxoGen (NASDAQ:AXGN) used its presentation at the 47th annual Raymond James Institutional Investors Conference to outline its mission to make restoration of peripheral nerve function an expected standard of care, while also providing updates on growth expectations, reimbursement progress, and the im
A Look At Axogen (AXGN) Valuation After Recent Share Price Pullback And BLA Expectations
Axogen stock moves after recent performance data Axogen (AXGN) has drawn fresh investor attention after recent performance figures showed a mixed return profile, with the share price slipping over the past week but remaining higher over the past three months and over the past year. See our latest analysis for Axogen. At a share price of US$32.50, Axogen’s recent 1 day and 7 day share price declines contrast with its stronger 90 day share price return of 13.84% and 1 year total shareholder...